Table 2. Participant characteristics pre-chemotherapy.
| Mean (SD) | % | |
|---|---|---|
| Age (years) | 48.3 (8.9) | |
| Age≥60 years | 11.5% | |
| European ethnicity† | 98.2% | |
| Height (m) | 1.64 (0.07) | |
| Weight* (kg) | 66.3 (12.1) | |
| BSA* (m2) | 1.72 (0.16) | |
| BSA >2.00 (m2) | 6.7% | |
| BMI* (kg/m2) | 24.7 (4.2) | |
| BMI ≥30 kg/m2 | 14.6% | |
| BMI ≥35 kg/m2† | 3.6% | |
| Systolic BP (mmHg) | 117.5 (15.4) | |
| Diastolic BP (mmHg) | 71.7 (10.3) | |
| Diagnosed hypertension† | 1.8% | |
| Baseline BP ≥160/100† | 1.8% | |
| Baseline BP ≥140/90mmHg | 11.0% | |
| Diabetes† | 0.6% | |
| Creatinine (μmol/l) | 68.2 (9.8) | |
| eGFR (ml/min/1.73m2) | 86.4 (15.4) | |
| ACE inhibitor, ARB or beta-blocker | 0% |
Compared with the general population of chemotherapy-treated breast cancer patients, the cohort was young with a low prevalence of cardiovascular risk factors.
*Geometric mean (approximate SD). ARB: angiotensin receptor blocker.
†Exclusion criteria identified after attending for CMR. As per protocol, these subjects continued in the study.